Clearbridge Health Announces Major Share Placement to Raise S\$3.87 Million
Date: 10 June 2026
By: Financial Reporter
Key Highlights
- Clearbridge Health Limited to issue 2,147,910,412 new ordinary shares via private placement.
- Issue price: S\$0.0018 per share – an 80% premium to the last traded VWAP of S\$0.0010.
- Total funds to be raised: S\$3,866,238.74.
- Three prominent investors: Ong Choon Yi, Vitters Sim Yu Xiong, and Xu Tianwei to collectively hold 33.33% of enlarged share capital post-placement.
- Net proceeds: Estimated at S\$3,766,000 (after S\$100k expenses), earmarked wholly for general working capital.
- Subscribers have no prior stake or relationship with the Company and are not acting in concert.
- Placement will not cause a change of control.
- Potential board representation: Ong Choon Yi and Vitters Sim Yu Xiong can each nominate a director to the Board.
Details of the Proposed Placement
Clearbridge Health Limited has entered into subscription agreements with three investors to issue over 2.1 billion new ordinary shares. The issue price represents an 80% premium to the prior day’s volume weighted average price, reflecting strong investor confidence and possibly a strategic move to shore up the company’s capital base at favorable terms.
- Investors and Allocation:
- Ong Choon Yi: 870,000,000 shares (13.5% of enlarged capital) – S\$1,566,000.
- Vitters Sim Yu Xiong: 961,910,412 shares (14.93%) – S\$1,731,438.74.
- Xu Tianwei: 316,000,000 shares (4.9%) – S\$568,800.
- None of the subscribers previously held shares in Clearbridge Health.
- All shares to be issued rank pari passu with existing shares except for dividends or distributions declared prior to issuance.
- Upon completion, Clearbridge Health’s share capital will expand from 4,295,820,825 to 6,443,731,237 shares, with the new shares representing about 33.33% of the enlarged capital base.
Strategic Rationale and Use of Proceeds
The entire net proceeds of S\$3.77 million are intended for general working capital purposes, aiming to strengthen the Group’s financial position and enable it to respond swiftly to business opportunities or challenges. This injection is expected to enhance the Group’s resilience and support long-term growth objectives.
Pending full deployment, proceeds may be placed in short-term deposits or money market instruments. The company commits to ongoing disclosure on the use of funds, including detailed breakdowns in annual reports and announcements.
Potential Impact on Shareholders and Share Price
- Substantial Dilution: The placement will dilute existing shareholders as the new shares represent 50% of the current share base and one-third of the enlarged base.
- Financial Effects:
- Net tangible asset (NTA) per share rises from S\$0.0256 to S\$0.0755.
- Loss per share (LPS) improves from S\$0.39 to S\$0.24 due to share base enlargement (losses unchanged).
- Premium Pricing: The 80% premium may signal strong investor endorsement and could support share price sentiment.
- Potential Board Influence: Two investors have the right to nominate directors, possibly impacting future strategic direction.
- No Change of Control: No single party gains control, and subscribers are not acting in concert.
- Regulatory and Listing Approvals Pending: Completion is subject to SGX Catalist approval and other standard conditions. There is no certainty the placement will proceed until all conditions are met.
- No introducer or commission fees payable.
Other Noteworthy Points
- Company has 659,999,996 outstanding warrants at S\$0.0024; the placement does not affect warrant terms.
- The placement is conducted under the general mandate approved in April 2026 and is within regulatory limits.
Key Risks and Caution
Important: The placement is subject to several conditions (incl. SGX approval, board resolutions, and non-occurrence of adverse events). There is no guarantee of completion.
Shareholders should note the significant dilution and the potential for changes in board composition. Any deviation in the use of proceeds or failure to complete the placement could affect company valuation and share price.
Directors’ and Shareholders’ Interests
None of the current directors or substantial shareholders (or their associates) have any direct or indirect interest in the placement, other than as shareholders or directors.
Document Inspection and Further Announcements
- Subscription Agreements are available for inspection at the company’s registered office for three months from the announcement date.
- Further updates will be provided as material developments occur.
Disclaimer
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Investors should consult their professional advisors and consider their own circumstances before making investment decisions. The placement remains subject to regulatory approvals and completion of conditions. There is no guarantee the transaction will proceed as announced.
清柏医疗（Clearbridge Health）拟私募发行逾21亿新股，筹资约386万新元
日期：2026年6月10日
作者：财经记者
要点摘要
- 清柏医疗有限公司将通过私募配售，发行2,147,910,412股新普通股。
- 每股发行价为S\$0.0018，较前一日成交量加权均价（S\$0.0010）溢价80%。
- 预计总计募资S\$3,866,238.74。
- 三位认购者：Ong Choon Yi、Vitters Sim Yu Xiong、Xu Tianwei，配售后将合计持有公司33.33%股份。
- 预计净筹资额约为S\$3,766,000（扣除S\$100,000费用），全部用于一般营运资金。
- 三位认购者此前均未持有公司股份，与公司及主要股东无关联或一致行动关系。
- 本次配售不会导致公司控股权变动。
- Ong Choon Yi和Vitters Sim Yu Xiong有权各自提名一名董事加入董事会。
配售详情
清柏医疗已与三位投资者签订认购协议，拟发行超21亿新股。本次发行价大幅高于市场价，显示投资者信心强劲，有助于公司以优厚条件增强资本实力。
- 认购分配：
- Ong Choon Yi：8.7亿股（13.5%），认购额S\$1,566,000。
- Vitters Sim Yu Xiong：9.619亿股（14.93%），S\$1,731,438.74。
- Xu Tianwei：3.16亿股（4.9%），S\$568,800。
- 本次发行后，公司总股本由42.96亿增至64.44亿股，新股占总股本33.33%。
- 新股与现有股份权利相同，除在配发前已宣派的股息或分派外。
配售动因与资金用途
所有净筹资额（约376.6万新元）将用于集团一般营运资金，增强财务状况，并把握未来业务机会。资金未全部动用前，可存放于短期存款或货币市场工具。公司将持续公告资金使用详情。
对股东及股价的潜在影响
- 显著稀释： 新股数量为原有股份的50%，占扩张后总股本三分之一，现有股东持股比例将显著下降。
- 财务影响：
- 每股净有形资产（NTA）由0.0256新元升至0.0755新元。
- 每股亏损（LPS）因股份基数增加由0.39新元降至0.24新元（亏损总额不变）。
- 溢价发行： 80%溢价或反映新投资者高度认可，对股价有正面支撑。
- 潜在董事会影响力变化： 两名投资者可各提名一董事，或影响公司战略方向。
- 无控股权变动： 无任何单一方控制公司，且认购者不存在一致行动关系。
- 监管与上市批准待定： 配售须获新交所Catalist批准及其他条件完成，存在不确定性。
- 无中介或佣金费用产生。
其他重要信息
- 公司有6.6亿余份尚未行权认股权证（行权价S\$0.0024），本次配售不影响其条款。
- 配售依2026年4月年度股东大会通过的一般授权进行，未超监管额度。
风险提示与注意事项
重要提示： 配售尚须满足多项条件（如新交所批准、董事会决议及无重大不利事件），存在未能完成的风险。
股东需关注股份稀释及董事会构成变动的可能性。若资金用途偏离预期或配售未能完成，或对公司估值及股价造成影响。
董事及主要股东利益
董事及主要股东（及其关联方）除作为普通股东或董事身份外，均不直接或间接参与本次配售。
文件查阅及后续公告
- 认购协议原件自公告日起三个月内，可于公司注册地址办公时间查阅。
- 公司将就配售进展及重大事项及时公告。
免责声明
本文仅供参考，不构成投资建议或买卖建议。投资者应结合自身实际，审慎决策，并咨询专业顾问。配售尚需监管批准及条件完成，存在不确定性。
